AU2015308345B9 - Compound and method - Google Patents

Compound and method Download PDF

Info

Publication number
AU2015308345B9
AU2015308345B9 AU2015308345A AU2015308345A AU2015308345B9 AU 2015308345 B9 AU2015308345 B9 AU 2015308345B9 AU 2015308345 A AU2015308345 A AU 2015308345A AU 2015308345 A AU2015308345 A AU 2015308345A AU 2015308345 B9 AU2015308345 B9 AU 2015308345B9
Authority
AU
Australia
Prior art keywords
cells
cell
subject
antigenic molecule
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015308345A
Other languages
English (en)
Other versions
AU2015308345A1 (en
AU2015308345B2 (en
Inventor
Anders Hogset
Pal Johansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PCI Biotech AS
Original Assignee
PCI Biotech AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201415247A external-priority patent/GB201415247D0/en
Priority claimed from GB201420773A external-priority patent/GB201420773D0/en
Application filed by PCI Biotech AS filed Critical PCI Biotech AS
Publication of AU2015308345A1 publication Critical patent/AU2015308345A1/en
Publication of AU2015308345B2 publication Critical patent/AU2015308345B2/en
Application granted granted Critical
Publication of AU2015308345B9 publication Critical patent/AU2015308345B9/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2015308345A 2014-08-28 2015-08-28 Compound and method Active AU2015308345B9 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB201415247A GB201415247D0 (en) 2014-08-28 2014-08-28 Compound and method
GB1415247.4 2014-08-28
GB1420773.2 2014-11-21
GB201420773A GB201420773D0 (en) 2014-11-21 2014-11-21 Compound and method
PCT/EP2015/069794 WO2016030529A1 (en) 2014-08-28 2015-08-28 Compound and method

Publications (3)

Publication Number Publication Date
AU2015308345A1 AU2015308345A1 (en) 2017-03-16
AU2015308345B2 AU2015308345B2 (en) 2020-12-10
AU2015308345B9 true AU2015308345B9 (en) 2020-12-24

Family

ID=54065872

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015308345A Active AU2015308345B9 (en) 2014-08-28 2015-08-28 Compound and method

Country Status (9)

Country Link
US (1) US10537639B2 (enExample)
EP (1) EP3185901B1 (enExample)
JP (2) JP2017526371A (enExample)
KR (1) KR102678732B1 (enExample)
CN (1) CN108136016A (enExample)
AU (1) AU2015308345B9 (enExample)
BR (1) BR112017003486A2 (enExample)
NZ (1) NZ729408A (enExample)
WO (1) WO2016030529A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109912607B (zh) * 2018-12-11 2021-01-22 南华大学 一类卟啉-白杨素复合物及其抗肿瘤活性
CN113453750A (zh) 2019-02-19 2021-09-28 大塚电子株式会社 光动力疗法条件参数的确定方法和光动力疗法装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013189663A1 (en) * 2012-05-15 2013-12-27 Pci Biotech As Conjugate of a photosensitiser and chitosan and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
KR20080080685A (ko) 2000-11-29 2008-09-04 피씨아이 바이오테크 에이에스 사이토졸 내로의 분자 전달을 위한 광화학적 내부이행
MXPA03005373A (es) 2000-12-13 2004-03-26 Inmunex Corp Metodo para generar lineas celulares dentriticas inmortales.
GB0121023D0 (en) 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
CA2545183C (en) * 2003-11-12 2017-01-17 Therion Biologics Corporation Custom vectors for treating and preventing pancreatic cancer
WO2005097976A1 (ja) * 2004-04-06 2005-10-20 Ehime University 抗原パルスして得られた樹状細胞
WO2005100547A1 (ja) * 2004-04-06 2005-10-27 Techno Network Shikoku Co., Ltd. 抗原パルスして得られた樹状細胞
WO2009149397A2 (en) 2008-06-06 2009-12-10 Baylor Research Institute Respiratory syncytial virus renders dendritic cells tolerogenic
US20120269765A1 (en) 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
US20160040128A1 (en) 2013-03-15 2016-02-11 Pci Biotech As Method
WO2015028575A1 (en) 2013-08-28 2015-03-05 Pci Biotech As Immunisation method by photochemical internalisation
CN105873585A (zh) 2013-08-28 2016-08-17 Pci生物技术公司 用于疫苗接种或免疫的化合物和方法
CA2945220C (en) 2014-04-11 2023-09-26 Pci Biotech As Method of treating melanoma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013189663A1 (en) * 2012-05-15 2013-12-27 Pci Biotech As Conjugate of a photosensitiser and chitosan and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLIVE KEVIN S ET AL, "Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?", EXPERT REVIEW OF VACCINES, EXPERT REVIEWS LTD, GB, (2010-05-01), vol. 9, no. 5, ISSN 1744-8395, pages 519 - 525 *
HÅKERUD MONIKA ET AL, "Intradermal photosensitisation facilitates stimulation of MHC class-I restricted CD8 T-cell responses of co-administered antigen", JOURNAL OF CONTROLLED RELEASE, (2013-11-23), vol. 174, , pages 143 - 150 *
WAECKERLE-MEN YING ET AL, "Photochemical targeting of antigens to the cytosol for stimulation of MHC class-I-restricted T-cell responses", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, (2013-02-24), vol. 85, no. 1, pages 34 - 41 *

Also Published As

Publication number Publication date
WO2016030529A1 (en) 2016-03-03
EP3185901C0 (en) 2023-10-04
NZ729408A (en) 2021-12-24
CN108136016A (zh) 2018-06-08
JP2020182486A (ja) 2020-11-12
AU2015308345A1 (en) 2017-03-16
EP3185901B1 (en) 2023-10-04
AU2015308345B2 (en) 2020-12-10
US10537639B2 (en) 2020-01-21
EP3185901A1 (en) 2017-07-05
KR102678732B1 (ko) 2024-06-25
US20170252441A1 (en) 2017-09-07
CA2959207A1 (en) 2016-03-03
KR20170047336A (ko) 2017-05-04
BR112017003486A2 (pt) 2018-01-16
JP7079819B2 (ja) 2022-06-02
JP2017526371A (ja) 2017-09-14

Similar Documents

Publication Publication Date Title
ES2676630T3 (es) Control inmunogénico de tumores y células tumorales
EP3038619B1 (en) Compound and method for vaccination and immunisation
Håkerud et al. Intradermal photosensitisation facilitates stimulation of MHC class-I restricted CD8 T-cell responses of co-administered antigen
JP6698541B2 (ja) 細胞性の細胞傷害性免疫応答を誘導または延長する方法における使用のための医薬
EP3265120B1 (en) Method
Haug et al. Photochemical internalization of peptide antigens provides a novel strategy to realize therapeutic cancer vaccination
CA2811957A1 (en) Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents
WO2018162498A1 (en) Peptides and methods for the treatment of diabetes
WO2007133728A1 (en) Photodynamic therapy-generated mesothelioma vaccine
JP7079819B2 (ja) 化合物および方法
US20160040128A1 (en) Method
Liu et al. Rabies virus lipopeptide conjugated to a TLR7 agonist improves the magnitude and quality of the Th1-biased humoral immune response in mice
CA2945220C (en) Method of treating melanoma
WO2015028575A1 (en) Immunisation method by photochemical internalisation
AU2018233208B2 (en) Immunopotentiator, immunotherapeutic pharmaceutical composition and its preparation and use
CA2959207C (en) Expression of an antigenic molecule on the surface of a cell using a photosensitizing agent and a cytokine
Brander et al. Peptide immunization in humans: a combined CD8+/CD4+ T cell-targeted vaccine restimulates the memory CD4 T cell response but fails to induce cytotoxic T lymphocytes (CTL)
US20190038740A1 (en) MHC Class I Associated Hepatitis B Peptides

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)